Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 20/20 | 1.00 |
| ▸ | DRD2 | P14416 | 15/20 | 1.00 |
| ▸ | DRD3 | P35462 | 14/20 | 1.00 |
| ▸ | DRD5 | P21918 | 4/20 | 1.00 |
| ▸ | F3 | P13726 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.91 |
| ▸ | HTR1A | P08908 | 1/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | CASP1 | P29466 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stepholidine SCHEMBL460434 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Stepholidine SCHEMBL10001965 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Stepholidine SCHEMBL10001966 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Stepholidine SCHEMBL29943869 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Corydalmine SCHEMBL21192512 | 0.94 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Corydalmine SCHEMBL12667453 | 0.94 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| Corydalmine SCHEMBL29243055 | 0.93 | DRD1 (0.98) | DRD1DRD2DRD3DRD5F3 | |
| SCHEMBL14703846 | 0.93 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| SCHEMBL680031 | 0.93 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 | |
| SCHEMBL29561422 | 0.93 | DRD1 (1.00) | DRD1DRD2DRD3DRD5F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| US-20230096103-A1 | BERBERINE COMPOUNDS, BERBERINE COMPOSITIONS, AND METHODS FOR ADMINISTRATION THEREOF | DIGNITY HEALTH | 2023-03-30 | — | — | US | claimed |
| CN-115398004-A | Berberine compounds, berberine compositions and methods of administration thereof | 尊严健康公司 | 2022-11-25 | — | — | CN | claimed |
| US-20260124143-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | OREXO AB (SE) | 2026-05-07 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4402138-B1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2025-08-27 | — | — | EP | disclosed |
| US-12115157-B2 | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-10-15 | — | — | US | disclosed |
| CN-115260185-B | Deuterated derivative of corydaline and stephanine and preparation method thereof | 杨征 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-115697997-B | Substituted 3-phenoxyazetidin-1-yl-pyrazines having GPR52 agonistic activity | 勃林格殷格翰国际有限公司 | 2024-07-30 | — | — | CN | disclosed |
| EP-4402138-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | Boehringer Ingelheim International GmbH (DE) | 2024-07-24 | — | — | EP | disclosed |
| US-20230131465-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| EP-4154866-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2023-03-29 | — | — | EP | disclosed |
| WO-2023041432-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-03-23 | — | — | WO | disclosed |
| EP-4126850-A1 | SUBSTITUTED 3-PHENOXYAZETIDIN-1-YL-PYRAZINES HAVING GPR52 AGONISTIC ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115398004-A | Berberine compounds, berberine compositions and methods of administration thereof | 尊严健康公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220356172-A1 | SUBSTITUTED 3-PHENOXYAZETIDIN-1-YL-PYRAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-11-10 | — | — | US | disclosed |
| CN-115260185-A | Deuterated derivatives of corydaline and stepholidine and preparation method thereof | 杨征 | 2022-11-01 | — | — | CN | disclosed |
| CN-109384780-B | Tetrahydro-protoberberine compounds, preparation method, application and pharmaceutical composition thereof | 中国科学院上海药物研究所 | 2022-04-08 | — | — | CN | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356172-A1 | SUBSTITUTED 3-PHENOXYAZETIDIN-1-YL-PYRAZINES | GPR52, GPR88, GPR65 | DRD1 655/4885DRD2 428/4885DRD3 791/4885 |
| US-20260124143-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | SLC5A1, SLC5A2, GLP1R | DRD1 1775/4885DRD2 1461/4885DRD3 1459/4885 |
| US-20230096103-A1 | BERBERINE COMPOUNDS, BERBERINE COMPOSITIONS, AND METHODS FOR ADMINISTRATION THEREOF | CBR3, BRD2, BRD3 | DRD1 22/4885DRD2 9/4885DRD3 12/4885 |
| US-12115157-B2 | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament | GPR52, GPR88, GPR68 | DRD1 427/4885DRD2 296/4885DRD3 676/4885 |
| US-20230131465-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | GPR52, GPR88, GPR68 | DRD1 427/4885DRD2 296/4885DRD3 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.